Zdrowie i gospodarka · 1.06.1998
Draft Guidance for Industry: Pilot Program for Electronic Investigational New Drug (eIND) Applications for Biological Products; Availability
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance document entitled ``Guidance for Industry: Pilot Program for electronic Investigational New Drug (eIND) Applications for Biological Products.'' This draft document, when finalized, is intended to provide guidance to sponsors on the design, development, organization, and submission of an eIND application to the Center for Biologics Evaluation and Research (CBER) as part of a pilot eIND program. This draft document is part of CBER's effort to develop, in cooperation with sponsors, an efficient process for electronic submissions of regulatory information relating to the development and marketing of biological products. Submissions in electronic format are voluntary.